613 results on '"Coyle, Patricia"'
Search Results
52. X-Ray Microbeam Irradiation of the Contusion-Injured Rat Spinal Cord Temporarily Improves Hind-Limb Function
53. Interleaved Carbon Minibeams: An Experimental Radiosurgery Method With Clinical Potential
54. DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Yes
55. Akkermansia muciniphila-Mediated Degradation of Host Mucin Expands the Tryptophan Utilizer Alistipes and Exacerbates Autoimmunity by Promoting Th17 Immune Responses
56. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age
57. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
58. Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
59. Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses
60. Symptom Management and Lifestyle Modifications in Multiple Sclerosis
61. Human T Lymphocyte Response to Borrelia burgdorferi Infection: No Correlation between Human Leukocyte Function Antigen Type 1 Peptide Response and Clinical Status
62. Immunoglobulin G Subclasses in Human Colostrum and Milk
63. What Can We Learn from Sex Differences in MS?
64. Transthyretin Sequesters Amyloid β Protein and Prevents Amyloid Formation
65. Switching Therapies in Multiple Sclerosis
66. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
67. sj-pdf-3-mso-10.1177_2055217321990852 - Supplemental material for Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study
68. sj-pdf-4-mso-10.1177_2055217321990852 - Supplemental material for Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study
69. sj-pdf-1-msj-10.1177_13524585211010294 – Supplemental material for Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
70. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
71. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 µg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study
72. Multiple Sclerosis in Pregnancy
73. Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis (2299)
74. Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active SPMS from the Phase 3 EXPAND Study (4649)
75. Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4+ T Cells
76. Switching algorithms: from one immunomodulatory agent to another
77. Additional file 1 of Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
78. Clinical neuroimmunology: multiple sclerosis and related disorders
79. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
80. Recent advances in the neuroimaging of multiple sclerosis
81. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study
82. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
83. A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma
84. Long-Term Cost Effectiveness of Interferon-β-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model
85. Normative data for the selective reminding test: a random digit dialing sample
86. Lyme disease
87. Lyme Disease
88. Pediatric Multiple Sclerosis: Just Like Their Elders?
89. Ofatumumab versus Teriflunomide in Multiple Sclerosis
90. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS
91. MRI features associated with rapid disease activity in clinically isolated syndrome patients at high risk for multiple sclerosis
92. Nrf2 differentially regulates pro- and anti-inflammatory function of Th17 cells through RORγT, SOD3 and Ahr
93. Encouraging and Measuring Practice Improvements Via Sequential Continuing Education (379)
94. Long-term Efficacy and Safety of Ponesimod, an oral S1P1 Receptor Modulator: Results from Randomized Phase II Core and Extension Studies in Relapsing-Remitting Multiple Sclerosis (1752)
95. Multiple Sclerosis Disease-Modifying Therapy: Recent Switch Patterns Among United States Neurologists (1296)
96. Changing Patterns in Disease-Modifying Therapy Selection for Treatment-Naive Multiple Sclerosis in the United States (1298)
97. Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry (1300)
98. B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356)
99. Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis (1845)
100. Clinical outcomes and treatment satisfaction in patients switching to teriflunomide in the real-world Teri-PRO and TAURUS-MS I studies (160)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.